Birabresib

Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Billion By 2026 Says Kuick Research Report

Retrieved on: 
Monday, August 31, 2020
Health, Medicine, Clinical medicine, Pharmaceutical industry, Cancer treatments, Antineoplastic drugs, Food and Drug Administration, Chemotherapy, Occupational safety and health, Clinical trial, Generic drug, Birabresib

NEW DELHI, Aug. 31, 2020 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage& Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Aug. 31, 2020 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage& Clinical Trials Insight 2026" Report Highlights:
    Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026
    USA Dominates Global Small Molecule Cancer Drug Market: >50% Share
    Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    770 Page Analysis With Graphical Representation of Drug Dosage, Sales, Price & Patent Insight
    Over the past few years, there has been an influx of cluster of innovative cancer therapies for the patients but the heightened excitement that small molecule cancer market has brought for wide variety of tumor types is approaching one-size-fits-all approach.
  • The discovery of small molecule cancer drugs for the cancer patients has brought a promising novel mechanism of treatment in the cancer patients.
  • More than 200 small molecule cancer drugs are commercially available in the market.
  • US along with China and UK accounts for more than 60% of the global small molecule cancer drugs trials.

Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Billion By 2026 Says Kuick Research Report

Retrieved on: 
Monday, August 31, 2020
Health, Medicine, Clinical medicine, Pharmaceutical industry, Cancer treatments, Antineoplastic drugs, Food and Drug Administration, Chemotherapy, Occupational safety and health, Clinical trial, Generic drug, Birabresib

NEW DELHI, Aug. 31, 2020 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage& Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Aug. 31, 2020 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage& Clinical Trials Insight 2026" Report Highlights:
    Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026
    USA Dominates Global Small Molecule Cancer Drug Market: >50% Share
    Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    770 Page Analysis With Graphical Representation of Drug Dosage, Sales, Price & Patent Insight
    Over the past few years, there has been an influx of cluster of innovative cancer therapies for the patients but the heightened excitement that small molecule cancer market has brought for wide variety of tumor types is approaching one-size-fits-all approach.
  • The discovery of small molecule cancer drugs for the cancer patients has brought a promising novel mechanism of treatment in the cancer patients.
  • More than 200 small molecule cancer drugs are commercially available in the market.
  • US along with China and UK accounts for more than 60% of the global small molecule cancer drugs trials.

Global Small Molecule Cancer Drug Market to 2026 - Drug Price, Dosage & Clinical Trials Insight - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020
Health, Pharmaceutical, Medicine, Clinical medicine, Cancer, Cancer treatments, Antineoplastic drugs, Chemotherapy, Occupational safety and health, Oncology, Treatment of cancer, Tyrosine kinase inhibitors, Birabresib, Vascular-targeting agent

The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The basic targeting advantage along with the dominance of small molecule drugs in cancer clinical pipeline will drive the global small molecule cancer drug market in coming years.
  • Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
    USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
    Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    An important parameter that should be associated with any of the cancer treatment is its specificity.
  • 3.2 Small Molecule Cancer Drug vs. Immunotherapy
    3.3 Small Molecule Cancer Drugs vs.

Global Glioblastoma Market Spotlight Report 2019: 10-year Disease Incidence Lorecast, Licensing and Acquisition Deals, Drug-Specific Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019
Health, General Health, Health, Medicine, Clinical medicine, Brain tumor, RTT, Oncology, Cancer, Glioblastoma, Novartis, Merck & Co., Birabresib

This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis.
  • There have been 41 licensing and asset acquisition deals involving glioblastoma drugs during 2014-19.
  • Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, followed by Roche and Novartis.